<DOC>
	<DOCNO>NCT01544114</DOCNO>
	<brief_summary>A 6 month study VIMOVO adolescent age 12-16 year juvenile idiopathic Arthritis ( JIA )</brief_summary>
	<brief_title>A Safety Study VIMOVO Adolescents With Juvenile Idiopathic Arthritis ( JIA )</brief_title>
	<detailed_description>A 6-month , Multicenter , Open-label , Safety Study VIMOVO ( 250 mg/20 mg , 375 mg/20 mg , 500 mg/20 mg Naproxen/Esomeprazole ) Adolescents Aged 12 16 Years , Inclusive , Juvenile Idiopathic Arthritis ( JIA )</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<criteria>Parent legal guardian able provide write informed consent patient able provide write assent appropriate . Male female adolescent age 12 16 year time enrollment . Diagnosed JIA , include ILAR JIA subtypes : oligoarthritis , polyarthritis ( RF+ RF ) , psoriatic arthritis , enthesitisrelated arthritis , undifferentiated arthritis , systemic arthritis . Based upon investigator judgment , determine appropriate patient undergo 6 month continuous treatment VIMOVO . Body weight &gt; 31 kg ( 68.2 lb ) within 5th 95th percentile body mass index age . In systemic JIA patient , presence systemic feature ( ie , fever , rheumatoid rash , serositis , lymphadenopathy , macrophage activation syndrome ) within 6 month prior start study drug . Currently take ( ie , within 4 week prior start drug ) naproxen &gt; 20 mg/kg/day &gt; 1000 mg total daily dose . Hemoglobin â‰¤8.5 g/dL . Individuals cardiovascular cerebrovascular disease , base history risk factor . Any significant hepatic , renal , pulmonary , ophthalmologic , neurologic , medical condition indicate medical/surgical history , physical , laboratory examination might put patient great risk study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>